Search
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalThe FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood. … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalIt is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable … Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets.
Products: Bromuro de pinaverio, BROMURO DE PINAVERIO 100 MG. TABLETASHyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitThe uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth
Pegzilarginase
go.drugbank.com/drugs/DB14780Approved[L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.
Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalIt is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of … tryptophan to 5-hydroxytryptophan via tryptophan hydroxylase.
Mecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalThe binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent … Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedThe neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps. … The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex.
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnPiperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. … Upon entry into the systemic circulation, the drug is partly oxidized and partly eliminated as an unchanged compound.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,